Skip to main content

Research Studies

Division of Hematology Research Studies

Find research studies available to children cared for by the Division of Hematology team.

Contact us

Recruitment Status

Study categories

Eligible age

Clinical trial phase

Gladiolus Study

This Phase 2 clinical research study is evaluating the safety and effectiveness of a once-daily oral investigational medicine that may improve anemia and reduce the need for red blood cell (RBC) transfusions among some patients who are chronically transfused. All participants enrolled in the study will receive the investigational medication.

We are currently enrolling individuals who meet the following criteria:*

  • Regular RBC transfusions to prevent stroke or recurrence of stroke (Cohort A)
  • Thalassemia and receiving regular RBC transfusions (Cohort B)
  • Thalassemia and not receiving regular RBC transfusions (Cohort C)

There are additional eligibility requirements, which the investigator will explain to you.

Phase: Phase II

Actively recruiting: No

Category: Adults, Children

Conditions: Alpha Thalassemia, Beta Thalassemia (Cooley's Anemia), Anemia

Panzyga Study

Immune Thrombocytopenia (ITP) is a blood disorder in which the immune system produces antibodies that attack and destroy the body's own blood platelets. The Panzyga Study is looking at a potential medicine (experimental drug) to see if it can result in increasing platelet counts and may potentially treat ITP. You will be infused with the experimental drug once or twice during the treatment period and will be followed up for 32 days. Testing will include blood tests, urine tests, pregnancy tests and physical exams. You may be able to take part in the study if you are below 18 years of age and have been diagnosed with chronic ITP.

Phase: Phase IV

Actively recruiting: No

Category: Children

Conditions: Idiopathic Thrombocytopenic Purpura (ITP)

Jump back to top